** Shares of New Zealand's Fisher & Paykel Healthcare Corp FPH.NZ up 1% at NZ$36.53
** The medical equipment maker to report FY25 results on Wednesday
** Morgan Stanley expects FY26 NPAT forecast of NZ$422 million ($253.16 million) vs Visible Alpha estimate of NZ$426 million
** Brokerage says FY26 forecasts imply limited gross margin expansion due to expected U.S. tariff impacts on products manufactured in New Zealand
** MS to focus on impacts from most recent U.S. flu season and trends for new applications growth in co's hospitals segment
** Brokerage also looking for co's updates on newer mask launches and commentary on potential impact of GLP-1s on the obstructive sleep apnea (OSA) market
** Stock rated "equal-weight" with a price target of NZ$36.7
** Fisher & Paykel down 5.1% YTD, including current session's moves
($1 = 1.6669 New Zealand dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。